Scientific Sessions 2024  /  Ischemic Heart Disease and Women  /  Cardiovascular And Obstetrical Outcomes In Women With Premature Coronary Artery Disease
Logo

American Heart Association

  139
  0

Final ID: MDP387

Cardiovascular And Obstetrical Outcomes In Women With Premature Coronary Artery Disease

Abstract Body (Do not enter title and authors here): Background: Premature coronary artery disease (CAD) is increasing, especially in young women. There is currently no data regarding the cardiovascular and obstetrical risk of pregnancy in patients with premature CAD.

Objective: This study aims to describe the cardiovascular, obstetrical and fetal outcomes in pregnant patients with premature CAD.

Methods: Using the AFIJI cohort of individuals with premature CAD (Appraisal of risk Factors in young Ischemic patients Justifying aggressive Intervention), we compared the cardiovascular outcomes of women aged < 40 years-old who experienced pregnancy versus those who did not. Major adverse cardiovascular events (MACE) including death, myocardial infarction, ischemic stroke, or unplanned revascularization were analyzed using a Cox model with pregnancy as a time-dependent variable. A secondary analysis described obstetrical and fetal outcomes in pregnant women with premature CAD vs. pregnant women of the French National maternal and fetal cohort (n=11992).

Results: Among women with premature CAD in the AFIJI cohort (N = 120), 50 were aged < 40 years among whom 24 experienced pregnancy. Aspirin was the only treatment continued during pregnancy. We observed an association between pregnancy and an increased risk of cardiovascular events (aHR 3.87, IC95% 1.41-10.63, p < 0.01) adjusted for age and tobacco use. When comparing with the French National database, pregnant women with premature CAD had higher rates of preeclampsia (20.8% vs. 2.3%), pregnancy-induced hypertension (37.5% vs. 2%), threat of premature birth (20.8% vs. 4.8%), postpartum hemorrhage (12.5% vs. 3%) and fetal death (8.7% vs. 0.8%).

Conclusion: Pregnancy in women with premature coronary artery disease is associated with a higher risk of major adverse cardiovascular events and significant more obstetrical complications. These findings highlight the need for careful monitoring and management of pregnant patients with a prior history of CAD to mitigate these risks.
  • Mikou, Meryem  ( Sorbonne Université , Paris , France )
  • Zeitouni, Michel  ( Sorbonne Université , Paris , France )
  • Procopi, Niki  ( Sorbonne Université , Paris , France )
  • Charleux, Pierre  ( Sorbonne Université , Paris , France )
  • Rahoual, Ghilas  ( Sorbonne Université , Paris , France )
  • Kerneis, Mathieu  ( Sorbonne Université , Paris , France )
  • Silvain, Johanne  ( Sorbonne University - APHP , Paris , Texas , United States )
  • Legrand, Lise  ( Sorbonne Université , Paris , France )
  • Nizard, Jacky  ( Sorbonne Université , Paris , France )
  • Montalescot, Gilles  ( Sorbonne Université , Paris , France )
    • Author Disclosures:
    Meryem MIKOU: DO NOT have relevant financial relationships | Michel Zeitouni: DO NOT have relevant financial relationships | Niki PROCOPI: No Answer | Pierre CHARLEUX: DO NOT have relevant financial relationships | Ghilas Rahoual: DO NOT have relevant financial relationships | Mathieu Kerneis: No Answer | Johanne Silvain: DO NOT have relevant financial relationships | Lise Legrand: No Answer | Jacky Nizard: No Answer | Gilles Montalescot: DO have relevant financial relationships ; Other (please indicate in the box next to the company name):Abbott : research or educational grant to the institution and consulting or lecture fees:Active (exists now) ; Other (please indicate in the box next to the company name):Terumo : research or educational grant to the institution and consulting or lecture fees:Past (completed) ; Other (please indicate in the box next to the company name):SMT : research or educational grant to the institution and consulting or lecture fees:Past (completed) ; Other (please indicate in the box next to the company name):Pfizer:Active (exists now) ; Other (please indicate in the box next to the company name):Novo Nordisk : research or educational grant to the institution and consulting or lecture fees:Past (completed) ; Other (please indicate in the box next to the company name):Lilly:Past (completed) ; Other (please indicate in the box next to the company name):Idorsia:Active (exists now) ; Other (please indicate in the box next to the company name):Hexacath:Past (completed) ; Other (please indicate in the box next to the company name):CSL Behring : research or educational grant to the institution and consulting or lecture fees:Past (completed) ; Other (please indicate in the box next to the company name):Celecor : research or educational grant to the institution and consulting or lecture fees:Past (completed) ; Other (please indicate in the box next to the company name):Boehringer Ingelheim : research or educational grant to the institution and consulting or lecture fees:Active (exists now) ; Other (please indicate in the box next to the company name):BMS : research or educational grant to the institution and consulting or lecture fees:Active (exists now) ; Other (please indicate in the box next to the company name):Bayer : research or educational grant to the institution and consulting or lecture fees:Past (completed) ; Other (please indicate in the box next to the company name):AstraZeneca : research or educational grant to the institution and consulting or lecture fees:Past (completed) ; Other (please indicate in the box next to the company name):Amgen : research or educational grant to the institution and consulting or lecture fees:Past (completed)
Meeting Info:

Scientific Sessions 2024

2024

Chicago, Illinois

Session Info:

Ischemic Heart Disease and Women

Saturday, 11/16/2024 , 09:30AM - 10:55AM

Moderated Digital Poster Session

More abstracts on this topic:
A novel method for measuring HDL-bound unconjugated bilirubin using an eel fluorescent protein reveals its association with reduced coronary artery disease

Fujioka Tomoo, Iino Takuya, Toh Ryuji, Harada Amane, Nagao Manabu, Shinohara Masakazu, Ishida Tatsuro, Otake Hiromasa

A Novel RNA Interference Agent RN0191 Lowering Proprotein Convertase Subtilisin/Kexin Type 9, Low-density Lipoprotein Cholesterol and Other Lipid Biomarkers in Healthy Volunteers with Elevated LDL Cholesterol: A Randomized, Single-blind, Placebo-controlled, Phase 1 Trial

Wang Fangfang, Li Haiyan, Zeng Jie, Shi Yibin, Li Hongmei

More abstracts from these authors:
Mineralocorticoid receptor antagonist in patients with acute myocardial infarction: An updated systematic review and meta-analysis of randomized trials

D'entremont Marc-andre, Montalescot Gilles, Zannad Faiez, Beygui Farzin, Pitt Bertram, Jolly Sanjit, Cheema Zain, Chauhan Ashwin, Kedev Sasko, Cornel Jan, Stankovic Goran, Moreno Raul, Storey Robert, Bossard Matthias

Pre-Hospital Antiplatelet Therapy In Patients With Out-Of-Hospital Cardiac Arrest Suspected Of Acute Coronary Syndrome

Charleux Pierre, Demoule Alexandre, Combes Alain, Silvain Johanne, Montalescot Gilles, Zeitouni Michel, Chommeloux Juliette, Elhadad Anthony, Procopi Niki, Guedeney Paul, Martinez Clelia, Rouanet Stephanie, Vicaut Eric, Kerneis Mathieu

4141212_File000000.jpg
4141212_File000000.jpg
You have to be authorized to contact abstract author. Please, Login
Not Available